Basilea Pharmaceutica AG (BSLN)

Switzerland
Currency in CHF
44.25
+0.60(+1.37%)
Closed·
BSLN Scorecard
Full Analysis
Valuation implies a strong free cash flow yield
Earnings results expected in 10 days
Fair Value
Day's Range
43.6044.40
52 wk Range
36.7548.75
Key Statistics
Edit
Bid/Ask
44.00 / 44.40
Prev. Close
43.65
Open
43.6
Day's Range
43.6-44.4
52 wk Range
36.75-48.75
Volume
50.18K
Average Vol. (3m)
50.5K
1-Year Change
1.37%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BSLN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
77.28
Upside
+74.65%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with low price volatility
Show more

Basilea Pharmaceutica AG Company Profile

Basilea Pharmaceutica AG engages in the discovering, developing, and commercializing drugs for bacterial or fungal infections. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis. It also develops Fosmanogepix, an antifungal drug for the treatment of Candidemia, which is in Phase II clinical trials; BAL2062 for invasive mold infections, which is in Phase I of clinical trials; and BAL2420, an antibiotics to treat severe Enterobacteriaceae infections. In addition, the company provides Zevtera, an antibiotic for the treatment of pneumonia, as well as develop for the treatment of Staphylococcus aureus bacteremia, acute bacterial skin, and skin structure infections. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.

Compare BSLN to Peers and Sector

Metrics to compare
BSLN
Peers
Sector
Relationship
P/E Ratio
7.0x−1.8x−0.5x
PEG Ratio
0.01−0.010.00
Price / Book
6.7x5.4x2.6x
Price / LTM Sales
2.6x4.7x3.0x
Upside (Analyst Target)
48.0%36.8%53.7%
Fair Value Upside
Unlock12.5%8.4%Unlock

Analyst Ratings

4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 77.28
(+74.65% Upside)

Earnings

Latest Release
Feb 18, 2025
EPS / Forecast
2.10 / 1.71
Revenue / Forecast
66.13M / 120.05M
EPS Revisions
Last 90 days

People Also Watch

3.34
ASCN
0.00%
39.09
SDZ
+1.80%
16.86
SIGNC
+0.72%
125.80
FOUG
+0.44%

FAQ

What Is the Basilea Pharmaceutica AG (BSLN) Stock Price Today?

The Basilea Pharmaceutica AG stock price today is 44.25

What Stock Exchange Does Basilea Pharmaceutica AG Trade On?

Basilea Pharmaceutica AG is listed and trades on the Switzerland Stock Exchange stock exchange.

What Is the Stock Symbol for Basilea Pharmaceutica AG?

The stock symbol for Basilea Pharmaceutica AG is "BSLN."

What Is the Basilea Pharmaceutica AG Market Cap?

As of today, Basilea Pharmaceutica AG market cap is 542.86M.

What Is Basilea Pharmaceutica AG's Earnings Per Share (TTM)?

The Basilea Pharmaceutica AG EPS (TTM) is 6.42.

When Is the Next Basilea Pharmaceutica AG Earnings Date?

Basilea Pharmaceutica AG will release its next earnings report on May 28, 2025.

From a Technical Analysis Perspective, Is BSLN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.